TRAILBLAZER-ALZ 2
TRAILBLAZER-ALZ 2 tested donanemab in early Alzheimer’s disease and is the main efficacy trial behind the US approval.
Overview
Phase 3, randomised, placebo-controlled. Clinical scale results favoured donanemab in the enrolled early-stage population. ARIA was the principal safety theme. Stopping after plaque clearance is a label discussion, not a community protocol.
- Numbers are not recorded here for this endpoint. Donanemab: Favoured versus placebo; Placebo.
- This endpoint is not one of the standard survival or response measures; read it alongside the trial's primary result.
- These results apply to the people the trial enrolled: Early Alzheimer’s disease. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Similar pages
not linked directly; found by shared links- TrialEXPEDITION 3
Shares Eli Lilly, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyApoE testing
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentRemternetug
Shares Eli Lilly, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyAnti-amyloid antibodies
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- TermARIA
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- IdeaAntibody trials that enrol mixed and comorbid disease
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- TargetAmyloid-beta
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- PersonAlois Alzheimer
Shares Alzheimer’s disease and the tag dementia-atlas.